Metformin, heart failure, and lactic acidosis: Is metformin absolutely contraindicated?

British Medical Journal

Volumn 335, Issue 7618, 2007, Pages 508-512

  Tahrani, A A ^a   Varughese, G I ^a   Scarpello, J H ^a   Hanna, F W F ^a  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; LACTIC ACID; METFORMIN; ORAL ANTIDIABETIC AGENT; PHENFORMIN; SULFONYLUREA;

ARTICLE; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; DRUG METABOLISM; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER CIRRHOSIS; LIVER FAILURE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RESPIRATORY FAILURE; RISK; SEPSIS; TREATMENT CONTRAINDICATION;

ACIDOSIS, LACTIC; DIABETES MELLITUS, TYPE 2; HEART FAILURE, CONGESTIVE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RISK FACTORS;

EID: 34548658535     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39255.669444.AE     Document Type: Article

References (20)

1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
2. Glucophage. www.fda.gov/medwatch/SAFETY/2004/mar_PI/Glucophage_PI.pdf (accessed 6 July 2007).
3. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;(1):CD002967.
4. Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD. Contraindications to metformin therapy in patients with type 2 diabetes - a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483-8.
5. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111:583-90.
6. Holstein A, Nahrwold D, Hinze S, Egberts EH. Contra-indications to metformin therapy are largely disregarded. Diabet Med 1999;16:692-6.
7. Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 2004;255:179-87.
8. Lalau JD, Race JM. Lactic acidosis in metformin-treated patients: prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf 1999;20:377-84.
9. Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998;21:1659-63.
10. Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002;162:434-7.
11. Horlen C, Malone R, Bryant B, Dennis B, Carey T, Pignone M, et al. Frequency of inappropriate metformin prescriptions. JAMA 2002;287:2504-5.
12. Rakovac I, Jeitler K, Gfrerer RJ, Habacher W, Seereiner S, Mrak P, et al. Patients with type 2 diabetes treated with metformin: prevalence of contraindications and their correlation with discontinuation. Diabet Med 2005;22:662-4.
13. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997;20:925-8.
14. Yap WS, Peterson GM, Vial JH, Randall CT, Greenaway TM. Review of management of type 2 diabetes mellitus. J Clin Pharm Ther 1998;23:457-65.
15. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004;27:1879-84.
16. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
17. Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hildebrandt P, Kober L, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 2004;43:771-7.
18. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005;28:2345-51.
19. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244-8.
20. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004;109:1004-9.